SCHEMBL20958121

SCHEMBL20958121

CC(C)c1c(O)nc(-n2ccnc2)nc1OCc1ccncn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 5/20 0.35
CYP3A4 P08684 3/20 0.34
CYP2D6 P10635 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
NOS3 P29474 4/20 0.33
NOS2 P35228 4/20 0.33
NOS1 P29475 7/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP2B6 P20813 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ENPP2 Q13822 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20958063 0.84 TSHR (0.42) CYP3A4CYP2D6CYP1A2CYP2C9NPC1
SCHEMBL20565354 0.81 CYP3A4 (0.41) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20957938 0.81 CYP3A4 (0.43) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20957951 0.80 CYP3A4 (0.46) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20564951 0.78 CD38 (0.40) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20564999 0.78 TSHR (0.39) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20957980 0.77 CYP1A2 (0.47) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20958060 0.76 CD38 (0.41) CD38CYP3A4CYP2D6NPC1TSHR
SCHEMBL20957961 0.75 CD38 (0.34) CD38CYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL20957952 0.75 CD38 (0.37) CD38CYP2D6CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135793-A1 HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE KDM5A, KDM5B, KDM5C CD38 791/4885CYP3A4 3097/4885CYP2D6 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.